Fructus Agni Casti
News and journals
Treatment of Premenstrual Syndrome with a Phytopharmaceutical Formulation Containing Vitex agnus castus
A multicentric noninterventional trial (open study without control) to investigate the efficacy and tolerance of a drug in a large number of patients under routine medical conditions was performed for a new solid preparation from an extract of the fruit of Vitex agnus castus (VAC, Vitex, chaste tree, Chasteberry) in 1634 patients suffering from premenstrual syndrome (PMS).
A specific questionnaire was developed for determining the effect of Vitex on psychic and somatic complaints, on the four characteristic PMS symptom complexes depression, anxiety, craving, and hyperhydration (DACH), and on single groups of symptoms.
After a treatment period of three menstrual cycles 93% of patients reported a decrease in the number of symptoms or even cessation of PMS complaints. To a certain extent, this effect was observed within all symptom complexes and correlated with the global assessment of therapeutic efficacy.
Whereas 85% of physicians rated it as good or very good, 81% of patients assessed their status after treatment as very much or much better. Analysis of frequency and severity of mastodynia as the predominant symptom revealed that complaints still present after 3 months of therapy were mostly less severe.
Ninety-four percent of patients assessed the tolerance of Vitex treatment as good or very good. Adverse drug reactions were suspected by physicians in 1.2% of patients, but there were no serious adverse drug reactions. Hence, the risk/benefit ratio of the new Vitex preparation can be rated as very good, with significant efficacy for all aspects of the multifaceted and inhomogeneous clinical picture of PMS, with a safety profile comparable to other Vitex preparations.
Effect of Vitex agnus Extract on MNU Induced Mammary Tumor of Sprague Dawley Rats
Published on:July 2017
Journal of Young Pharmacists, 2017; 9(3):367-370
Original Article | doi:10.5530/jyp.2017.9.73
Maninder Kour1, Vinodini Nithyananda Madom Anantharaya1, Kumar Megur Ramakrishna Bhat2, Shrijeet Chakraborti3, Bhagyalakshmi Kodavanji1
1Department of Physiology, KMC Mangalore, Manipal University, Karnataka, INDIA.
2Department of Anatomy, Raas Al Khaimah, UAE.
3Department of Pathology, KMC Mangalore, Manipal University, Karnataka, INDIA.
Background: Breast cancer is one of the most serious and life taking etiologies of the present time. The cause and treatment of breast cancer still remains the major concern of medical and health sciences. The Vitex agnus also known as Vitex agnus castus(VAC) or Vitex nirgundi is used for many reproductive problems of females and widely used for the treatment of pre-menstrual stress syndrome and cyclical breast pain. The extract is used in the present study to see its anticancer effect in mammary tumors. The objective of the study was to investigate the in-vivo anticancer effect of hydroalcoholic extract of Vitex agnus in ameliorating the mammary tumor of the SD rats.
Methodology: A 30 day old inbred Sprague dawley (SD) female rats of body weight 70-80 grams were taken for this study. The rats were induced with MNU for mammary tumor development. After the development of palpable and visible tumor the rats were given a hydroalcoholic extract of Vitex agnus.Serum MDA and GSH were measured to check the pro and antioxidant potential of Vitex agnus.
Results: Histopathological findings showed the regression features in the tumor of the rats treated with Vitex agnus extract indicating the positive treatment of mammary tumor and improved oxidative status of the tissue was evident by increase in the levels of GSH and decreased levels of serum MDA levels which in turn is an indicator of reduced oxidative stress of the tissue.
Conclusion:Therefore, this study suggests that Vitex agnus extract can be useful for the treatment as well as improvement of oxidative status of the mammary tumor tissue.
Key words: Breast Cancer, Vitex agnus Castus, Histopathology, GSH, MDA, Sprague Dawley.
More information: http://www.jyoungpharm.org/article/1020